Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (TSM) Reaches $36.50 52-Week High; Shorts at Cytomx Therapeutics (CTMX) Lowered By 0.41%

June 5, 2017 - By Marie Mckinney

The stock of Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) hit a new 52-week high and has $37.60 target or 3.00% above today’s $36.50 share price. The 7 months bullish chart indicates low risk for the $183.20B company. The 1-year high was reported on Jun, 5 by Barchart.com. If the $37.60 price target is reached, the company will be worth $5.50 billion more. About 943,207 shares traded. Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) has risen 51.40% since June 5, 2016 and is uptrending. It has outperformed by 34.70% the S&P500.

Cytomx Therapeutics Incorporated (NASDAQ:CTMX) had a decrease of 0.41% in short interest. CTMX’s SI was 770,600 shares in June as released by FINRA. Its down 0.41% from 773,800 shares previously. With 179,200 avg volume, 4 days are for Cytomx Therapeutics Incorporated (NASDAQ:CTMX)’s short sellers to cover CTMX’s short positions. The SI to Cytomx Therapeutics Incorporated’s float is 3.72%. About 32,851 shares traded. CytomX Therapeutics Inc (NASDAQ:CTMX) has risen 50.10% since June 5, 2016 and is uptrending. It has outperformed by 33.40% the S&P500.

Among 5 analysts covering Taiwan Semiconductor Manufacturing (NYSE:TSM), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Taiwan Semiconductor Manufacturing had 8 analyst reports since August 24, 2015 according to SRatingsIntel. Susquehanna upgraded Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) on Tuesday, October 4 to “Neutral” rating. The company was downgraded on Tuesday, June 28 by Goldman Sachs. On Thursday, October 13 the stock rating was downgraded by HSBC to “Hold”. The stock of Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) has “Sector Weight” rating given on Friday, October 14 by Pacific Crest. The stock of Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) has “Outperform” rating given on Friday, December 11 by Credit Suisse.

Analysts await Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM) to report earnings on July, 13. They expect $0.43 earnings per share, 0.00% or $0.00 from last year’s $0.43 per share. TSM’s profit will be $2.16B for 21.22 P/E if the $0.43 EPS becomes a reality. After $0.54 actual earnings per share reported by Taiwan Semiconductor Mfg. Co. Ltd. (ADR) for the previous quarter, Wall Street now forecasts -20.37% negative EPS growth.

Taiwan Semiconductor Manufacturing Company Limited is a semiconductor foundry. The company has market cap of $183.20 billion. The Firm is engaged in the manufacturing, selling, packaging, testing and computer-aided design of integrated circuits and other semiconductor devices and the manufacturing of masks. It has a 15.95 P/E ratio. It operates through foundry segment.

Among 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. CytomX Therapeutics had 4 analyst reports since November 2, 2015 according to SRatingsIntel. Cowen & Co initiated the stock with “Outperform” rating in Monday, November 2 report. The firm has “Outperform” rating given on Monday, November 2 by Oppenheimer. Jefferies initiated the shares of CTMX in report on Monday, November 2 with “Buy” rating. The company was downgraded on Tuesday, January 3 by Oppenheimer.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The company has market cap of $514.12 million. The Firm uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. It currently has negative earnings. The Company’s pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.